[Correspondence] Adequate SIRT activity dose is as important as adequate chemotherapy dose

In their Article, Harpreet Wasan and colleagues1 reported a combined analysis of three prospective randomised controlled trials (SIRFLOX, FOXFIRE, and FOXFIRE-Global) that compared a regimen of first-line leucovorin, fluorouracil, and oxaliplatin (FOLFOX) plus selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres with FOLFOX alone in patients with colorectal cancer with liver metastases. They found no survival benefit for the FOLFOX plus SIRT group (median overall survival 22·6 months [95% CI 21·0–24·5] with FOLFOX plus SIRT vs 23·3 months [21·8–24·7] with FOLFOX alone; p=0·61).

http://ift.tt/2z1DHDN